The possible mechanism affecting the development of tumors is the excessive activation or inhibition of GLP-1R expression
Additionally, lixisenatide was associated with fewer gastrointestinal symptoms compared to exenatide, while long-acting GLP-1RAs generally caused less nausea and vomiting but more diarrhea than short-acting agents (49)
The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)
It's a food quality strategy
costs for GLP-1 drugs In the U.S., GLP-1 drugs can often be covered by insurance and Medicare, depending on what you are using them for
February 2024 Ozempic, Mounjaro and Other GLP-1 Lawsuit Update The new findings were released within a week of the U.S